Epsilogen announces significant expansion of management team with three new senior hires
26.4.2023 09:00:00 EEST | Business Wire | Press release
Epsilogen Ltd, a global leader in the development of novel immunoglobulin E (IgE) antibodies to treat cancer, announced three new senior hires in what is a significant expansion of their management team. Nick Robbins-Cherry joins as Chief Financial Officer, Andrew Calam as Vice President of Clinical Operations and Elizabeth Hardaker as Vice President of Biology.
Nick Robbins-Cherry, CFO, brings over 30 years of experience in fundraising, public markets and private equity, gained through financial and commercial roles in international pharmaceuticals and technology businesses. Most recently, Nick was CFO of Ixaka Ltd, a private cell and gene therapy company. Prior to this, Nick was CFO at Midatech Pharma PLC, a listed pharmaceutical business with operations in the UK and Spain. He successfully steered Midatech through its IPO on AIM, a dual listing on NASDAQ and subsequent fundraises. Nick is a Chartered Accountant and holds an MBA.
Andrew Calam, VP of Clinical Operations, has over 25 years of experience in the life sciences industry, holding both management and executive positions in the contract research organisation (CRO) and biotechnology sectors, leading and supporting pharmaceutical development. Andrew started his career within the bioanalytical space, before turning his focus to project management. He has a track record of leading multinational teams with responsibility for all aspects of clinical trial management from phase I to phase III trials. Prior to joining Epsilogen, Andrew worked as an Executive Director of Clinical Development at Syneos Health where he was responsible for the development, oversight, execution and management of several clinical programs for targeted cancer therapies.
Elizabeth Hardaker, VP of Biology, joins Epsilogen with over 15 years’ experience in the pharmaceutical industry. Most recently, Elizabeth was a Senior Director at AstraZeneca, leading a team supporting preclinical research in Oncology. Previously, Elizabeth worked at Evotec in the inflammation and immunology group, and Novartis in the respiratory group. Throughout her career Elizabeth has been the biology lead on a number of projects across the drug discovery process, ranging from target validation to clinical trials. Elizabeth has a PhD from the National Heart and Lung Institute, Imperial College and a Masters in Biochemistry from Bath University.
Tim Wilson, Chief Executive Officer of Epsilogen, commented:
“We are delighted to have Elizabeth, Andrew and Nick join our leadership team and we are pleased that we have been able to attract such high-calibre people to Epsilogen. They join the Company at an exciting stage of its development with lead asset MOv18 IgE having successfully completed a phase I clinical trial in ovarian cancer patients and progress being made within our IgE-based therapeutic platforms.”
ENDS
About Epsilogen Ltd
Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE’s natural function is to provide immunological defense against certain parasites. This functionality makes it an ideal treatment of solid tumours due to its strong potency, enhanced tumour access and long tissue half-life.
Epsilogen’s lead product candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic and encouraging data from a phase I trial demonstrated MOv18 IgE to be safe and well tolerated with early signs of clinical activity also seen. The company is also developing a proprietary IGEGTM antibody platform combining elements from both IgE and IgG antibodies into novel and proprietary antibody molecules with enhanced functionality.
Epsilogen began operations in 2017 as a spin out of King’s College London and has attracted investment funding from top tier investors including Epidarex Capital, Novartis Venture Fund, British Patient Capital, 3B Future Health Fund, ALSA Ventures and Schroders Capital. Find out more at epsilogen.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230425005971/en/
Contact information
Communications advisor to Epsilogen Ltd:
Simon Conway / Rob Winder
FTI Consulting
epsilogen@fticonsulting.com
+44 (0)20 3727 1000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Svante & Meadow Lake Tribal Council Partnership Agrees to Sell Microsoft 626,000 Tonnes of Carbon Removal Credits6.4.2026 18:00:00 EEST | Press release
Svante Technologies Inc. (Svante) and Meadow Lake Tribal Council (MLTC) announced today that North Star Carbon Solutions LP has entered into an offtake agreement with Microsoft to deliver 626,000 tonnes of durable carbon dioxide removal (CDR) credits to be delivered over 15 years from the North Star bioenergy with carbon capture and storage (BECCS) project in Saskatchewan, Canada. The project is being developed through a partnership between MLTC and Svante and will be co-located at the MLTC Bioenergy Centre in Meadow Lake. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260406630377/en/ As part of the project, a new carbon capture plant will be established at the MLTC Bioenergy Centre, a renewable power generation facility supplied by sustainable waste biomass from the adjacent sawmill owned by MLTC and other local forest product mills. The new plant will be owned by North Star Carbon Solutions LP, a partnership between MLTC
Textron Aviation Names Five 2026 Top Hawk Recipients as Program Enters Its Second Decade of Workforce Impact6.4.2026 18:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced Brazos Valley Flight Services, Executive Air Taxi Corporation, Fairmont State University, Sterling Flight Training and Victors Aviation as its 2026 Top Hawk program recipients, continuing a legacy that has placed 55 factory-new Cessna Skyhawks in training environments since the program launched in 2015. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260402481685/en/ Factory-new Cessna Skyhawks (Model 172) to take flight as Textron Aviation names five 2026 Top Hawk recipients—helping train the next generation of pilots Now entering its second decade, Top Hawk is one of the industry’s longest‑running manufacturer‑school partnerships. Designed to support aviation workforce development, the program loans custom‑branded, factory‑new Skyhawks to selected organizations for one year, giving students access to the world’s most popular training aircraft and help
The Spectrum of Global Cinema Unfolds in Jeonju: The 27th JEONJU International Film Festival6.4.2026 16:23:00 EEST | Press release
The 27th JEONJU International Film Festival (JIFF) is set to run from April 29 to May 8 in Jeonju, featuring 237 movies from 54 countries. Jeonju—the most authentic Korean city and a prominent tourist destination in Asia known for its tradition and cuisine—will host this year’s film festival under the slogan “Beyond the Frame.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260406890043/en/ The 27th JEONJU International Film Festival will take place from April 29 to May 8 in Jeonju (Image: JEONJU CITY) Opening the 27th edition will be Kent Jones’s “Late Fame,” while the film “The Longest Night: Namtaeryong” directed by Kim Hyun-ji will close the festival. In addition, a special program honors the late Korean actor Ahn Sung-ki, who passed away last year. Titled “Special Focus: Ahn Sung-ki’s Memorable Films Yet Rarely Seen,” it showcases seven of his films to pay tribute to a distinguished acting career defined by ceaseless ar
Enry’s Island Unveils “Enry’s Island Adventures”: Venture Capital Becomes a Videogame and Launches the “Strap” Movement on Kickstarter3.4.2026 10:47:00 EEST | Press release
Enry’s Island SpA (WBAG: EIOS), the world’s first publicly traded Venture Builder, today announced the upcoming Kickstarter launch of Enry’s Island Adventures (EIA), developed by its New York-based portfolio company, Enry’s Island Adventures LLC. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260402548535/en/ The game is designed to make venture capital accessible to new generations, transforming startup creation into an engaging and social gaming experience. After three years of R&D, EIA introduces a "bleisure" model (business + leisure): players learn to launch and manage startups through gameplay that includes real business KPIs, a customizable and evolving personal island, synchronous and asynchronous multiplayer modes, social events, and community-driven seasonal missions. The “VC revolution”: teaching and democratizing through play "I agree with Elon Musk that the best way to teach is through a video game, and this is
SES Announces Results of the Annual General Meeting2.4.2026 17:49:00 EEST | Press release
SES (the “Company”) held the Annual General Meeting (“AGM”) of Shareholders today in Betzdorf, Luxembourg. Following the recommendations made by the Board of Directors of SES, the shareholders have voted in favor of all resolutions, including the Company’s 2025 annual accounts and the proposed annual dividend of EUR 0.50 per A-share (EUR 0.20 per B-share). The total dividend amount comprises the interim dividend of EUR 0.25 per A-share (EUR 0.10 per B-share), which has already been paid to shareholders on October 16, 2025. The final dividend of EUR 0.25 per A-share (EUR 0.10 per B-share) will be paid to shareholders on April 16, 2026. “I would like to sincerely thank our shareholders for their active engagement, visionary support and continued confidence in SES’ strategy,” said Adel Al-Saleh, CEO of SES. “The outcomes of today’s AGM underscore our shared commitment to a bold multi-orbit approach, with Medium Earth Orbit as the strategic backbone of a dynamically evolving global interco
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom